Boval BioSolutions Acquired By Proliant
Proliant Biologicals, LLC (Proliant), an LGI company (Lauridsen Group Inc.), today announced that it has acquired Boval BioSolutions from Lifecycle Biotechnologies of Fort Worth, TX. The acquisition concluded on September 2, 2019 and financial terms of the deal were not disclosed.
According to Stephen Welch, President of Proliant, “Boval possesses proprietary technologies that align well with Proliant’s core strengths. This acquisition will further strengthen Proliant’s position as the industry leader in protein fractionation and albumin manufacturing. We are excited to welcome all of Boval’s customers and are eager to work with them to ensure business continuity, while providing an unparalleled level of supply security and technological innovation.”
Proliant has a robust pipeline of new products to broaden its folio as it continues to seek innovative ways to serve the markets it operates within. Among the new products are Alburich™ and Precision Grade™ BSA, both of which target specific applications within the IVD and biologics manufacturing markets. The addition of Boval further enhances Proliant’s ability to bring value and innovation to its customers.
“With nearly four decades of protein fractionation expertise and unmatched, state-of-the-art manufacturing facilities in two hemispheres, Proliant is in a unique position to supply Bovals’ customers with high quality BSA.” said Cody Yarborough, president of Boval. “It is a great fit, we could not be happier to see our products and technologies come under Proliant’s leadership and to know our customers will be well served.”
To read the full press release, click here.